股票骗局有哪些-中信证券app-【东方资本】,a股交易t 几,t0开通条件,专业线上配资

科學(xué)文獻

我們與學(xué)術(shù)機構(gòu)開展合作研究，以評估我們的管線產(chǎn)品。以下是發(fā)表的相關(guān)文獻。

年：

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, […]

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma

D Hoda, R Richards, EA.Faber, A Deol, D Porter, BD. Hun […]

Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, IncludingTriple-Class Exposure in the United States

S Jagannath, N Joseph, J He, C Crivera, AZ Fu, A Garret […]

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delfo […]

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

AD Cohen, S Parekh, BD Santomasso, JG Pérez-Larraya, N […]

本網(wǎng)站使用Cookies來改善您的整體體驗，讓您下次訪問網(wǎng)站時更加輕松快捷，為您帶來更好的服務(wù)。具體內(nèi)容請參閱隱私政策 Cookie政策。

<tbody id="gxup2"></tbody>

<dd id="gxup2"></dd>

<tbody id="gxup2"><small id="gxup2"><center id="gxup2"></center></small></tbody>

<dfn id="gxup2"></dfn>

<strong id="gxup2"><acronym id="gxup2"></acronym></strong>